Cencora, formerly AmerisourceBergen, is a pharmaceutical distributor and services company headquartered in Conshohocken, Pennsylvania, supplying medicines and healthcare products to pharmacies, hospitals and clinics.
Is this your business? Add your evidence →
Cencora's Scope 1 emissions are up 28% on its FY2019 base and its combined Scope 1 and 2 are slightly above it, while its stated Scope 3 grew to 46.1 Mt in FY2025. Renewable electricity is about 20%, it publishes no biodiversity assessment, and 67% of its waste is diverted. It has an SBTi-validated absolute target for FY2032 but has made no net progress, and its UK subsidiary moved its net-zero date from 2030 to 2040.
Cencora scores 33/100 (Below expectations) on SINK's independent climate assessment, scored from public data only. Fees pay for the review, never the result. Last verified October 2026.
That places Cencora joint 539th of 847 companies scored, and joint 18th of 19 in Healthcare / Pharmaceuticals.
Cencora is tied at the bottom of the healthcare / pharmaceuticals pack.
Among the 19 major healthcare / pharmaceuticals brands we've scored, Cencora is tied =18th of 19, with 1 other.
Its three lowest-scoring questions, and what the evidence didn't show.
Scope 3 grew from 19.9M MT (FY2019) to 46.1M MT (FY2025).
Fiscal 2025 report and GRI index contain no biodiversity, deforestation or TNFD disclosure.
Reports ~1.98M cubic metres for FY2025 based on engineering estimate (sanitary and cooling tower use), not metered data.
A score changes when the evidence does. We use new published evidence at the next rescore. Evidence that isn't public can count through an evidence review.
Use this score in tenders
Send the link, or the one-page score sheet. It links back to this page and every source. Free.
Open the score sheet →Add your evidence, £99
Scored low because little is published? Send us your evidence. A person reviews it and your score reflects what you really do. Done within 5 working days.
Evidence review →Go tender-ready, £495 a year
A yearly rescore, a check of up to 25 key suppliers and a score badge for your website (coming soon).
Get in touch →Strongest on Carbon Footprint — Operations and Carbon Footprint — Supply Chain (8/10, 7/10). Weakest on Emissions Trajectory and Nature & Biodiversity Impact (1/10, 2/10).
The 3 companies in the sector scoring nearest above Cencora.
J&J's Scope 1 and 2 emissions fell 38% from 2021, mostly through renewable electricity instruments including unbundled certificates; Scope 1 itself fell only about 3% from 2023 to 2025.
See the breakdown →CVS Health's Scope 1 and 2 emissions are down 43% since 2019 with reasonable assurance, though Scope 1 rose in 2025, and its Scope 3 total of 26.3 Mt has not fallen steadily.
See the breakdown →Cardinal Health reports Scope 1, 2 and 3 emissions with third-party assurance, but its Scope 1 and 2 are only 17% below FY2019 against a 50% cut targeted for FY2030.
See the breakdown →The formula and all 11 sources.
Same ten questions for every company. No private weighting.
SINK = (0.3 × Base + 0.7 × Performance) × Scale11 sources used in this assessment. All publicly available. Each row shows which of the ten questions it informed.
“Our Scope 1 emissions for fiscal 2025 were 189,955 MT CO2e.”
“Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements”
“AmerisourceBergen also commits that 82% of its suppliers by spend, covering purchased goods and services, will have science-based targets by FY2027.”
“Our total Scope 3 emissions for FY24 were 40,504,084 MT CO2e.”
“Solar photovoltaic systems help power operations, reducing our carbon footprint while ensuring operational resilience.”
“Cencora, Chiesi Group”
“Oversees the Company's sustainability, corporate responsibility and inclusion strategy, and the Company's related reporting and disclosure practices.”
“Business Roundtable $157,500”
“Bob Mauch is the President and Chief Executive Officer of Cencora, Inc.”
If you believe a source has been misread or a newer version exists, submit a challenge.
Cencora, formerly AmerisourceBergen, is a pharmaceutical distributor and services company headquartered in Conshohocken, Pennsylvania, supplying medicines and healthcare products to pharmacies, hospitals and clinics. Incorporated in Delaware in 2001, it had about 51,000 employees and $321.3 billion in FY2025 revenue.
One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.
No spam. Unsubscribe in one click.
Checking a company?
Search free →Asked to prove you're sustainable?
Get your business scored, free →Been scored?
See what's behind your number →Fees pay for the review, never the result.